{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:56:19Z","timestamp":1787068579901,"version":"build-2736575974"},"reference-count":40,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["POR"],"DOI":"10.2147\/por.s361907","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T01:10:05Z","timestamp":1660093805000},"page":"75-84","source":"Crossref","is-referenced-by-count":8,"title":["A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Na\u00efve Adult Indian Patients Living with HIV-1"],"prefix":"10.2147","volume":"Volume 13","author":[{"given":"Ameet","family":"Dravid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dnyanesh","family":"Morkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwijendra","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T","family":"Ramapuram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik Vikrambhai","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K Sunil","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Bhrusundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Anuradha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddabathuni","family":"Nageswaramma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surabhi","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thammisetty","family":"Jayaprakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9781-6230","authenticated-orcid":true,"given":"Vinay","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2014733","DOI":"10.1080\/21645515.2021.2014733","volume":"18","author":"Rashid","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"ref2","unstructured":"National AIDS Control Organisation & ICMR-National Institute of Medical Statistics. India HIV estimates 2020: technical brief; 2020. Available from: naco.gov.in. Accessed on July 14, 2022."},{"key":"ref3","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 9789241549684_eng.pdf; 2016. Available from: who.int. Accessed August 17, 2021."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/infdis\/jiaa683","volume":"224","author":"Bertagnolio","year":"2021","journal-title":"J Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12981-019-0220-8","volume":"16","author":"Rutstein","year":"2019","journal-title":"AIDS Res Ther"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/cid\/civ102","volume":"60","author":"Kantor","year":"2015","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1473-3099(11)70255-9","volume":"12","author":"Hamers","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"ref9","unstructured":"World Health Organization. Guidelines on the public health response to pretreatment HIV drug resistance. Geneva: World Health Organization. 9789241550055-eng.pdf; 2017. Available from: who.int. Accessed August 20, 2021."},{"key":"ref10","unstructured":"World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization; 2019. Available from: WHO-CDS-HIV-19.15-eng.pdf. Accessed August 20, 2021."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.eclinm.2020.100573","volume":"28","author":"Kanters","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","volume":"7","author":"Calmy","year":"2020","journal-title":"Lancet HIV"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1186\/s12879-019-4389-1","volume":"23","author":"Weng","year":"2019","journal-title":"BMC Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/COH.0000000000000388","volume":"12","author":"Cahn","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e1003421","DOI":"10.1371\/journal.pmed.1003421","volume":"10","author":"Sculier","year":"2020","journal-title":"PLoS Med"},{"key":"ref16","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021. Available from: who.int. Accessed August 21, 2021."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/hiv.12878","volume":"21","author":"Ryom","year":"2020","journal-title":"HIV Med"},{"key":"ref18","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services; 2021."},{"key":"ref19","unstructured":"Ahmed N, Angus B, Boffito M, et al. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. treatment-guidelines-2016-interim-update.pdf; 2015. Available from. bhiva.org. Accessed August 21, 2021."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12879-021-05850-0","volume":"21","author":"Nickel","year":"2021","journal-title":"BMC Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12879-019-3975-6","volume":"19","author":"Snedecor","year":"2019","journal-title":"BMC Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3018(16)30091-1","volume":"3","author":"Kanters","year":"2016","journal-title":"Lancet HIV"},{"key":"ref23","unstructured":"National Guidelines for HIV care and treatment. National AIDS control organization. National_Guidelines_for_HIV_Care_and_Treatment_2021.pdf; 2021. Available from. naco.gov.in. Accessed June 15, 2022."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","volume":"70","author":"Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","volume":"6","author":"Aboud","year":"2019","journal-title":"Lancet HIV"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1093\/jac\/dkaa319","volume":"75","author":"Calza","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1177\/0956462416688127","volume":"28","author":"Todd","year":"2017","journal-title":"Int J STD AIDS"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1016\/S2352-3018(17)30152-2","volume":"4","author":"Wijting","year":"2017","journal-title":"Lancet HIV"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","volume":"381","author":"Namsal","year":"2019","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1093\/cid\/ciy763","volume":"68","author":"Kumarasamy","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ejhpharm-2020-002374","volume":"29","author":"Fern\u00e1ndez-Bargiela","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e25085","DOI":"10.1002\/jia2.25085","volume":"21","author":"Zheng","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"ref38","unstructured":"The Joint United Nations Programme on HIV\/AIDS. Ending AIDS: progress Towards the 90-90-90 Targets. Geneva: joint United Nations Programme on HIV\/AIDS. Global_AIDS_update_2017_en.pdf; 2017. Available from: unaids.org. Accessed on August 17, 2021."},{"key":"ref39","unstructured":"National AIDS Control Organization (2020). Sankalak: status of National AIDS Response (Second edition, 2020). New Delhi: NACO, Ministry of Health and Family Welfare, Government of India. Sankalak Status of National AIDS Response, Second Edition (2020); 2020. Available from: pdf.naco.gov.in. Accessed August 17, 2021."},{"key":"ref40","unstructured":"National AIDS control organization. National technical guidelines on anti-retroviral treatment; 2018. NACO-National Technical Guidelines on ART_October.2018.1.pdf."}],"container-title":["Pragmatic and Observational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=82891","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=82891","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T01:10:25Z","timestamp":1660093825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/a-phase-iv-study-on-safety-tolerability-and-efficacy-of-dolutegravir-l-peer-reviewed-fulltext-article-POR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":40,"URL":"https:\/\/doi.org\/10.2147\/por.s361907","relation":{},"ISSN":["1179-7266"],"issn-type":[{"value":"1179-7266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}